

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/050016 A1

(51) International Patent Classification:

C07D 471/14 (2006.01) A61P 35/00 (2006.01)
A61K 31/4353 (2006.01)

(21) International Application Number:

PCT/US2024/044830

(22) International Filing Date:

30 August 2024 (30.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/580,207	01 September 2023 (01.09.2023)	US
63/607,009	06 December 2023 (06.12.2023)	US
63/572,811	01 April 2024 (01.04.2024)	US
63/665,613	28 June 2024 (28.06.2024)	US

(71) Applicant: **TREELINE BIOSCIENCES, INC.** [US/US];
500 ARSENAL STREET, Watertown, Massachusetts
02472 (US).

(72) Inventors: **OBERG, Kevin M.**; 11180 Roselle Street, Suite A, San Diego, California 92121 (US). **HANSEN, Joshua D.**; 11180 Roselle Street, Suite A, San Diego, California 92121 (US). **CORREA, Matthew D.**; 11180 Roselle Street, Suite A, San Diego, California 92121 (US). **MARRONE, Tami J.**; 11180 Roselle Street, Suite A, San Diego, California 92121 (US). **MCNEILL, Matthew H.**; 11180 Roselle Street, Suite A, San Diego, California 92121 (US). **NAGY, Mark A.**; 11180 Roselle Street, Suite A, San Diego, California 92121 (US). **SCHLEICHER, Kristin D.**; 11180 Roselle Street, Suite A, San Diego, California 92121 (US). **VALIERE, Andrew**; 11180 Roselle Street, Suite A, San Diego, California 92121 (US).

(74) Agent: **KIM, Gina** et al.; GOODWIN PROCTER LLP, 100 NORTHERN AVENUE, IP DOCKETING DEPT./7TH FLOOR, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS

(57) Abstract: This disclosure provides compounds of Formula (I) (e.g., Formula (I-1), Formula (I-2), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), or (I-a-4)), Formula (I-b) (e.g., Formula (I-b-1), (I-b-2), (I-b-3), or (I-b-4)), Formula (I-c) (e.g., Formula (I-c-1) or (I-c-2)), Formula (I-d) (e.g., Formula (I-d-1)), or Formula (I-e) (e.g., Formula (I-e-1) or (I-e-2))), Formula (II), or Formula (II-a) (e.g., Formula (II-a-1)), or pharmaceutically acceptable salts thereof, that induce degradation of a BCL6 protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions containing the compounds provided herein, or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.



WO 2025/050016 A1